A CVS Health white paper using Aetna claims data finds GLP-1s offset their full cost to plan sponsors only at $350 per month — well below current employer prices of $617–$766 monthly.

DRUG PRICING · GLP-1 PRICING · NOVEMBER 18, 2026 · UNITED STATES
At the HLTH 2026 conference in Las Vegas, CVS Health — the Rhode Island-based pharmacy benefit manager (PBM), insurer, and pharmacy retailer — released a white paper that converts a familiar employer complaint into a specific number: GLP-1 drugs for weight loss and related conditions break even for plan sponsors only when priced at or below $350 per month over a three-year period, according to the company’s analysis of anonymized claims from Aetna members in fully insured plans.
Employers typically pay between $617 and $766 a month for GLP-1s, according to Employee Benefit Research Institute (EBRI) data cited by Healthcare Dive. At current prices, the white paper found, pharmacy spending on GLP-1s outweighs the medical savings for plan sponsors — even as the drugs demonstrably improve health outcomes.
$350/mo
CVS Health’s white paper estimates GLP-1s break even for plan sponsors at $350 per month over three years — versus the $617–$766 employers currently pay, per the Employee Benefit Research Institute.
What the Aetna data show
The study tracked Aetna members who took GLP-1s from 2023 to 2025, with some patients accumulating three years of follow-up. Among those who remained on the drugs for three years, total medical spending decreased by $9,400, but associated pharmacy spending increased by $13,300 over the same period, per the Fierce Healthcare report of the white paper — a net $3,900 in additional costs per person taking GLP-1s, according to Healthcare Dive. The study also found hospitalizations fell between 34% and 42% over three years, and patients had 14% lower odds of a serious cardiac event. The study also found obesity rates declining after a 2022 peak.
Amy Compton-Phillips, M.D., chief medical officer at CVS Health, told Fierce Healthcare that the drugs gained steam as a treatment for obesity at a high price, and that while costs have come down, the reductions have not yet been enough to offset expenditures. She framed the $350 threshold as the price point that would likely draw employers into broader coverage: ‘For them, it might be really worthwhile to say, Hey, at this price point, I can afford to cover this for my employees, knowing that in the near term the savings will pay for my investment.’
In a May 2026 Bloomberg interview, CVS Health chief executive officer David Joyner said GLP-1 prices need to fall below what Medicare is paying — Medicare having announced a program to cover Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy at a rate of $245 a month starting July 1, according to Bloomberg. The November white paper’s $350 figure sits above that Medicare reference rate but well below the EBRI employer range.
A formulary lever already in use
CVS Health’s Caremark unit has already acted on price. In May 2025, Caremark announced it would give Wegovy preferred access on its standard formulary — which covers tens of millions of Americans — effective July 1, 2025, under a deal with Novo Nordisk, displacing Zepbound, according to Healthcare Dive. Eli Lilly’s stock fell more than 7% following the news, according to Healthcare Dive. In May 2026, CVS said it would restore Zepbound to its commercial formularies as an additional preferred option effective October 1, 2026, after Eli Lilly agreed to cut the price it charges many health plans, Bloomberg reported; a CVS spokesperson said the change is expected to save health plans 10% to 15% on their obesity drug costs. On HealthSignals’ reading, that sequence suggests the $350 figure also works as a public negotiating position.
The global GLP-1 market is expected to reach $190 billion by 2035, $40 billion more than a prior estimate, as the weight-loss drug market expands, according to Morgan Stanley, as cited by Healthcare Dive. The drugs generated $79 billion in total sales in 2025, per the same report. CVS Health’s analysis notes that more than 137 million U.S. adults are medically eligible for semaglutide across indications, with many qualifying under more than one, according to Healthcare Dive.
Workforce turnover adds a separate problem, Compton-Phillips said. Even when GLP-1s do generate downstream medical savings, an employer may not capture those savings if an employee changes jobs before they are realized — having already paid for the medication. This dynamic could, on HealthSignals’ reading, make self-insured large employers with lower turnover more receptive to the $350 threshold than smaller or higher-churn plan sponsors.
Adherence compounds the access problem. The study found that clinical improvements fell off when patients could not remain on the medication over several years. Compton-Phillips said there is ‘not great evidence’ that patients who come off the drugs maintain the weight loss. CVS Health’s own weight management program pairs the prescription with nutrition support, peer coaching, and other wraparound services, a model the company presents as addressing adherence.
What to Watch
- Eli Lilly and Novo Nordisk responses to the $350 monthly benchmark — whether either manufacturer moves list or net prices toward that threshold in commercial plan negotiations
- Caremark’s next formulary cycle: whether the $350 figure is operationalized as a coverage condition or rebate floor in plan-sponsor contracts
- Zepbound’s return to Caremark commercial formularies as an additional preferred option on October 1, 2026 — a live test of whether restored dual-drug access shifts employer coverage decisions
GLP-1 Economics · Three-Year Horizon
| CVS Health Break-Even | Employer/Plan Sponsor Range (EBRI) | Medicare Rate | |
|---|---|---|---|
| Monthly price | $350 | $617–$766 | $245 |
| Aetna claims, members on GLP-1s for three years | Change |
|---|---|
| Medical spending | −$9,400 |
| Pharmacy spending | +$13,300 |
| Hospitalizations | −34% to −42% |
| Odds of a serious cardiac event | −14% |
Sources: CVS Health white paper via Fierce Healthcare; Employee Benefit Research Institute via Healthcare Dive; Bloomberg
Why this is relevant
Patients
CVS Health’s chief medical officer argues that GLP-1 prices of $350 per month would draw employers into broader coverage, potentially broadening access for the more than 137 million U.S. adults the company estimates are medically eligible for semaglutide across indications.
Industry
Eli Lilly and Novo Nordisk face a named, public price benchmark from CVS Health’s Caremark, a pharmacy benefit manager (PBM) that has already shifted formulary preference between Zepbound and Wegovy based on price concessions, and says restoring Zepbound will save health plans 10% to 15% on obesity drug costs.
Payers
Among Aetna members on GLP-1s for three years, pharmacy spending rose $13,300 while medical spending fell $9,400, a net cost of $3,900 per user; Compton-Phillips flagged workforce turnover as a further obstacle to employers capturing savings.
Caregivers
CVS Health’s chief medical officer Amy Compton-Phillips said there is ‘not great evidence’ that patients maintain weight loss after stopping a GLP-1, and the study found clinical gains fell off when patients could not stay on therapy.
Sources: Fierce Healthcare: HLTH 2026 — New CVS study aims to identify the right price for GLP-1s · Healthcare Dive: CVS white paper aims to pressure drugmakers to lower GLP-1 prices · Bloomberg: Obesity drug prices undercut healthcare savings, CVS CEO says · Bloomberg: CVS returns Zepbound to drug plans after Lilly slashes price · Healthcare Dive: CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







